Access cutting-edge hemophilia treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access hemophilia specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hemophilia treatment provided free
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Sponsor: Pfizer
Check if you qualify for this hemophilia clinical trial in New York, NY
If you're searching for hemophilia treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hemophilia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.